Cargando…

Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction

Background: The farnesoid X receptor (FXR) is a key factor regulating hepatic bile acid synthesis and enterohepatic circulation. Repression of bile acid synthesis by the FXR is a potential strategy for treating cholestatic liver disease. However, the role of intestinal FXR on the intestinal barrier...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Meng, Hou, Li, Cai, Yaoyao, Wang, Hanfei, Ma, Yujun, Geng, Qiming, Jiang, Weiwei, Tang, Weibing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234329/
https://www.ncbi.nlm.nih.gov/pubmed/35770078
http://dx.doi.org/10.3389/fphar.2022.906452
_version_ 1784736047180021760
author Yan, Meng
Hou, Li
Cai, Yaoyao
Wang, Hanfei
Ma, Yujun
Geng, Qiming
Jiang, Weiwei
Tang, Weibing
author_facet Yan, Meng
Hou, Li
Cai, Yaoyao
Wang, Hanfei
Ma, Yujun
Geng, Qiming
Jiang, Weiwei
Tang, Weibing
author_sort Yan, Meng
collection PubMed
description Background: The farnesoid X receptor (FXR) is a key factor regulating hepatic bile acid synthesis and enterohepatic circulation. Repression of bile acid synthesis by the FXR is a potential strategy for treating cholestatic liver disease. However, the role of intestinal FXR on the intestinal barrier and intestinal microbiota needs further investigation. Materials: Intestinal tissues were collected from patients with biliary atresia or without hepatobiliary disease. Then, intestinal mRNA levels of FXR-related molecules were determined. To investigate the effect of FXR activation, bile-duct-ligation rats were treated with obeticholic acid [OCA (5 mg/kg/day)] or vehicle (0.5% methyl cellulose) per oral gavage for 14 days. The mRNA levels of intestinal FXR, SHP, TNF-α, FGF15 and bile acid transporter levels were determined. In addition, the intestinal permeability, morphologic changes, and composition of the intestinal microbiota were evaluated. Gut Microbiome was determined by 16S rDNA MiSeq sequencing, and functional profiling of microbial communities was predicted with BugBase and PICRUSt2. Finally, the role of OCA in injured intestinal epithelial cell apoptosis and proliferation was examined by pretreatment with lipopolysaccharide (LPS) in Caco-2 cells. Results: The downstream of the FXR in ileum tissues was inhibited in biliary obstruction. Activation of the FXR signaling pathway by OCA significantly reduced liver fibrosis and intestinal inflammation, improved intestinal microbiota, and protected intestinal mucosa in BDL rats. OCA also altered the functional capacities of ileum microbiota in BDL rats. Significant differences existed between the controls and BDL rats, which were attenuated by OCA in the alpha diversity analysis. Principal coordinates analysis showed that microbial communities in BDL rats clustered separately from controls, and OCA treatment attenuated the distinction. Bugbase and PICRUSt2 analysis showed that OCA changed the composition and structure of the intestinal microbiota and improved the metabolic function of the intestinal microbiota by increasing the relative abundance of beneficial bacteria and reducing the relative abundance of harmful bacteria. Moreover, OCA reduced the apoptosis induced by LPS in Caco-2 cells. Conclusion: The FXR agonist, OCA, activates the intestinal FXR signaling pathway and improves the composition and structure of the intestinal microbiota and intestinal barrier in BDL rats.
format Online
Article
Text
id pubmed-9234329
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92343292022-06-28 Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction Yan, Meng Hou, Li Cai, Yaoyao Wang, Hanfei Ma, Yujun Geng, Qiming Jiang, Weiwei Tang, Weibing Front Pharmacol Pharmacology Background: The farnesoid X receptor (FXR) is a key factor regulating hepatic bile acid synthesis and enterohepatic circulation. Repression of bile acid synthesis by the FXR is a potential strategy for treating cholestatic liver disease. However, the role of intestinal FXR on the intestinal barrier and intestinal microbiota needs further investigation. Materials: Intestinal tissues were collected from patients with biliary atresia or without hepatobiliary disease. Then, intestinal mRNA levels of FXR-related molecules were determined. To investigate the effect of FXR activation, bile-duct-ligation rats were treated with obeticholic acid [OCA (5 mg/kg/day)] or vehicle (0.5% methyl cellulose) per oral gavage for 14 days. The mRNA levels of intestinal FXR, SHP, TNF-α, FGF15 and bile acid transporter levels were determined. In addition, the intestinal permeability, morphologic changes, and composition of the intestinal microbiota were evaluated. Gut Microbiome was determined by 16S rDNA MiSeq sequencing, and functional profiling of microbial communities was predicted with BugBase and PICRUSt2. Finally, the role of OCA in injured intestinal epithelial cell apoptosis and proliferation was examined by pretreatment with lipopolysaccharide (LPS) in Caco-2 cells. Results: The downstream of the FXR in ileum tissues was inhibited in biliary obstruction. Activation of the FXR signaling pathway by OCA significantly reduced liver fibrosis and intestinal inflammation, improved intestinal microbiota, and protected intestinal mucosa in BDL rats. OCA also altered the functional capacities of ileum microbiota in BDL rats. Significant differences existed between the controls and BDL rats, which were attenuated by OCA in the alpha diversity analysis. Principal coordinates analysis showed that microbial communities in BDL rats clustered separately from controls, and OCA treatment attenuated the distinction. Bugbase and PICRUSt2 analysis showed that OCA changed the composition and structure of the intestinal microbiota and improved the metabolic function of the intestinal microbiota by increasing the relative abundance of beneficial bacteria and reducing the relative abundance of harmful bacteria. Moreover, OCA reduced the apoptosis induced by LPS in Caco-2 cells. Conclusion: The FXR agonist, OCA, activates the intestinal FXR signaling pathway and improves the composition and structure of the intestinal microbiota and intestinal barrier in BDL rats. Frontiers Media S.A. 2022-06-13 /pmc/articles/PMC9234329/ /pubmed/35770078 http://dx.doi.org/10.3389/fphar.2022.906452 Text en Copyright © 2022 Yan, Hou, Cai, Wang, Ma, Geng, Jiang and Tang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yan, Meng
Hou, Li
Cai, Yaoyao
Wang, Hanfei
Ma, Yujun
Geng, Qiming
Jiang, Weiwei
Tang, Weibing
Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction
title Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction
title_full Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction
title_fullStr Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction
title_full_unstemmed Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction
title_short Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction
title_sort effects of intestinal fxr-related molecules on intestinal mucosal barriers in biliary tract obstruction
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234329/
https://www.ncbi.nlm.nih.gov/pubmed/35770078
http://dx.doi.org/10.3389/fphar.2022.906452
work_keys_str_mv AT yanmeng effectsofintestinalfxrrelatedmoleculesonintestinalmucosalbarriersinbiliarytractobstruction
AT houli effectsofintestinalfxrrelatedmoleculesonintestinalmucosalbarriersinbiliarytractobstruction
AT caiyaoyao effectsofintestinalfxrrelatedmoleculesonintestinalmucosalbarriersinbiliarytractobstruction
AT wanghanfei effectsofintestinalfxrrelatedmoleculesonintestinalmucosalbarriersinbiliarytractobstruction
AT mayujun effectsofintestinalfxrrelatedmoleculesonintestinalmucosalbarriersinbiliarytractobstruction
AT gengqiming effectsofintestinalfxrrelatedmoleculesonintestinalmucosalbarriersinbiliarytractobstruction
AT jiangweiwei effectsofintestinalfxrrelatedmoleculesonintestinalmucosalbarriersinbiliarytractobstruction
AT tangweibing effectsofintestinalfxrrelatedmoleculesonintestinalmucosalbarriersinbiliarytractobstruction